Minerva Neurosciences, Inc. (NERV) stock
NERVNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.20−0.10 (-4.35%)
Close on Nov 16, 2026Market cap $105.05MP/E –Yield –
Minerva Neurosciences r&d expenses
Research and development expenses are spending on new products and technology.
Minerva Neurosciences's R&D Expenses for the twelve months ending Jun 30, 2026 was $15.54M, up 137.9% year over year. For fiscal 2025 it was $5.76M, down 51.6% from the year before. Over ten years it grew -11.0% a year on average. The highest annual figure on record is $58.12M in fiscal 2019.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.76M | -51.6% |
| FY2024 | Dec 31, 2024 | $11.90M | -6.3% |
| FY2023 | Dec 31, 2023 | $12.71M | -13.3% |
| FY2022 | Dec 31, 2022 | $14.65M | -54.3% |
| FY2021 | Dec 31, 2021 | $32.04M | +45.4% |
| FY2020 | Dec 31, 2020 | $22.04M | -62.1% |
| FY2019 | Dec 31, 2019 | $58.12M | +66.6% |
| FY2018 | Dec 31, 2018 | $34.89M | +15.3% |
| FY2017 | Dec 31, 2017 | $30.26M | +48.0% |
| FY2016 | Dec 31, 2016 | $20.44M | +10.3% |
| FY2015 | Dec 31, 2015 | $18.53M | -56.8% |
| FY2014 | Dec 31, 2014 | $42.91M | +5956.3% |
| FY2013 | Dec 31, 2013 | $708.49K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $7.19M | +453.7% |
| Q1 FY2026 | Mar 31, 2026 | $5.25M | +285.7% |
| Q4 FY2025 | Dec 31, 2025 | $2.17M | +9.6% |
| Q3 FY2025 | Sep 30, 2025 | $925.38K | -51.0% |
| Q2 FY2025 | Jun 30, 2025 | $1.30M | -66.4% |
| Q1 FY2025 | Mar 31, 2025 | $1.36M | -67.3% |
| Q4 FY2024 | Dec 31, 2024 | $1.98M | -58.0% |
| Q3 FY2024 | Sep 30, 2024 | $1.89M | -45.2% |
| Q2 FY2024 | Jun 30, 2024 | $3.86M | +104.5% |
| Q1 FY2024 | Mar 31, 2024 | $4.17M | +57.0% |
| Q4 FY2023 | Dec 31, 2023 | $4.72M | +48.0% |
| Q3 FY2023 | Sep 30, 2023 | $3.44M | +45.5% |
| Q2 FY2023 | Jun 30, 2023 | $1.89M | -54.3% |
| Q1 FY2023 | Mar 31, 2023 | $2.65M | -46.5% |
| Q4 FY2022 | Dec 31, 2022 | $3.19M | -83.0% |
| Q3 FY2022 | Sep 30, 2022 | $2.37M | -47.5% |
| Q2 FY2022 | Jun 30, 2022 | $4.13M | -25.2% |
| Q1 FY2022 | Mar 31, 2022 | $4.96M | +52.2% |
| Q4 FY2021 | Dec 31, 2021 | $18.75M | +427.9% |
| Q3 FY2021 | Sep 30, 2021 | $4.51M | -2.7% |
| Q2 FY2021 | Jun 30, 2021 | $5.52M | -4.3% |
| Q1 FY2021 | Mar 31, 2021 | $3.26M | -59.7% |
| Q4 FY2020 | Dec 31, 2020 | $3.55M | -87.5% |
| Q3 FY2020 | Sep 30, 2020 | $4.64M | -52.1% |
| Q2 FY2020 | Jun 30, 2020 | $5.77M | -30.7% |
| Q1 FY2020 | Mar 31, 2020 | $8.08M | -30.4% |
| Q4 FY2019 | Dec 31, 2019 | $28.52M | +216.7% |
| Q3 FY2019 | Sep 30, 2019 | $9.67M | +15.6% |
| Q2 FY2019 | Jun 30, 2019 | $8.32M | -8.2% |
| Q1 FY2019 | Mar 31, 2019 | $11.61M | +37.4% |
| Q4 FY2018 | Dec 31, 2018 | $9.01M | +37.7% |
| Q3 FY2018 | Sep 30, 2018 | $8.37M | -6.6% |
| Q2 FY2018 | Jun 30, 2018 | $9.06M | +26.8% |
| Q1 FY2018 | Mar 31, 2018 | $8.45M | +11.0% |
| Q4 FY2017 | Dec 31, 2017 | $6.54M | +0.7% |
| Q3 FY2017 | Sep 30, 2017 | $8.96M | +53.0% |
| Q2 FY2017 | Jun 30, 2017 | $7.14M | – |
| Q1 FY2017 | Mar 31, 2017 | $7.61M | – |
| Q4 FY2016 | Dec 31, 2016 | $6.50M | – |
| Q3 FY2016 | Sep 30, 2016 | $5.85M | – |
See a number that looks wrong?